Skip to main content
Videos

Nivolumab Plus Ipilimumab Yields Superior PFS vs Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer

First Results from CheckMate 8HW Study

Featuring Thierry André, MD


Thierry Andre, MD, Sorbonne Université, and Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Paris, France, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high (MSI-high), mismatch repair-deficient (dMMR) metastatic colorectal cancer. These results report progression-free survival (PFS) by blinded independent central review at a prespecified interim analysis.


Source:

Andre T, Elez E, Van Cutsem E, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. Presented at 2024 ASCO Gastrointestinal Cancer Symposium; January 18-20, 2024; San Francisco, California. Abstract LBA 768

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.